Corporate and financial executive with more than thirty years of experience in finance and administration roles with increasing responsibilities, including M&A, financing rounds, advisor to CEOs and CFOs. Trained in Business and Accounting at Concordia University (CPA and MBA degrees), she is recognized for her analyzing skills and rapid understanding of long-term corporate growth challenges.

Through her extensive experience in the biotech industry and other sectors, she developed an acute sense for nailing down sound strategies and identifying potential financial risks and opportunities.

Totally accustomed to key corporate areas such as budget, administration or forecasting, Micheline has been part of the comprehensive M&A process that led to the acquisition of Inversago Pharma by Novo Nordisk in August 2023, for up to 1.075 billion dollars US.

• 

  Chief Executive Officer (CEO) in Inversago Pharma

  Transformative therapies for the treatment of metabolic and fibrotic diseases

• 

  President in Inversago Pharma

  Transformative therapies for the treatment of metabolic and fibrotic diseases